Cadrenal Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for CVKD, updated each market day.
CVKD AI Sentiment
AI sees no strong directional signal for Cadrenal Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
Sector
Exchange
Market Cap
$3,995,703
Cap Tier
Employees
5
Headquarters
PONTE VEDRA, FL
Listed Since
Jan. 20, 2023
Website
CVKD Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CVKD Volatility
Cadrenal Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
